+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immuno Oncology Assays Market by Product, Technology, Indication, Application - Global Forecast to 2024

  • ID: 4752892
  • Report
  • Region: Global
  • 109 Pages
  • Markets and Markets
1 of 6
The Increasing Adoption of Targeted Therapy Over Traditional Therapy is Expected to Drive the Overall Growth of the Immuno-Oncology Assays Market

FEATURED COMPANIES

  • Foundation Medicine
  • Illumina, Inc.
  • Merck
  • Perkinelmer
  • Qiagen
  • Roche Diagnostics
  • MORE

Immuno Oncology Assays Market by Product (Consumables, Software), Technology (Immunoassay, Flow Cytometry, PCR, Next Generation Sequencing), Indication (Lung Cancer, Colorectal Cancer), Application (Research, Clinical Diagnostics) - Global Forecast to 2024

“The increasing adoption of targeted therapy over traditional therapy is expected to drive the overall growth of the immuno-oncology assays market.”

The immuno-oncology assays market is expected to grow from USD 2.9 billion in 2018 to USD 5.9 billion by 2024, at a CAGR of 12.7% during the forecast period. The immuno-oncology assays market is driven primarily by factors such as the increasing adoption of targeted therapy over traditional therapy and the increasing demand for mAbs. However, the high cost of immunotherapy treatment and the high attrition rate in the product development cycle are the major factors that are expected to restrain the growth of this market during the forecast period.

“The lung cancer segment is expected to grow at the highest CAGR during the forecast period.”

Based on indication, the immuno-oncology assays market is segmented into lung cancer, colorectal cancer, melanoma, bladder cancer, and other cancers. The lung cancer segment is expected to be the fastest-growing segment during the forecast period, as major players are focusing on immuno-oncology research for lung cancer owing to its increasing incidence.

“Asia Pacific projected to grow at the highest CAGR during the forecast period.”

The Asia Pacific is projected to record the highest growth rate during the forecast period. Factors such as the growing number of CROs in the region, increasing awareness about early detection of cancer, and the shift of manufacturers’ and suppliers’ focus from developed economies to emerging economies, such as India and China are driving the growth of this regional segment.

In-depth interviews were conducted with Chief Executive Officers (CEOs), marketing directors, other innovation and technology directors, and executives from various key organizations operating in the immuno-oncology assays market.

  • By Company Type: Tier 1: 18%, Tier 2: 39%, and Tier 3: 43%
  • By Designation: C-level Executives: 25%, Directors: 20%, and Others: 55%
  • By Region: North America: 40%, Europe: 27%, APAC: 20%, and RoW: 13%

The immuno-oncology assays market comprises major providers such as Thermo Fischer Scientific (US), Roche Diagnostics (Switzerland), Agilent Technologies (US), and Illumina (US). The study includes an in-depth competitive analysis of these key players in the immuno-oncology assays market, along with their company profiles, recent developments, and key market strategies.

Research Coverage:
The market study covers the immuno-oncology assays market across various segments. It aims at estimating the market size and the growth potential of this market across different segments, on the basis of product, technology, application, indication, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall immuno-oncology assays market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, and opportunities.

Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Foundation Medicine
  • Illumina, Inc.
  • Merck
  • Perkinelmer
  • Qiagen
  • Roche Diagnostics
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Covered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Primary Data
2.1.1 Key Data From Primary Sources
2.1.2 Key Industry Insights
2.2 Secondary Data
2.2.1 Key Data From Secondary Sources
2.3 Market Size Estimation
2.4 Market Breakdown and Data Triangulation
2.4.1 Assumptions for the Study

3 Executive Summary

4 Premium Insights
4.1 Immuno-Oncology Assays: Market Overview
4.2 North America: Immuno-Oncology Assays Market, By Product and Country (2018)
4.3 Immuno-Oncology Assays Market, By Application (2018 vs 2024)
4.4 Immuno-Oncology Assays Market, By Technology (2018 vs 2024)
4.5 Geographical Snapshot of the Immuno-Oncology Assays Market

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Incidence of Cancer and Increasing Adoption of Targeted Therapy
5.2.2 Restraints
5.2.2.1 Unfavorable Regulatory and Reimbursement Scenario
5.2.2.2 High Amount of Capital Investments and Low Benefit-Cost Ratio
5.2.3 Opportunities
5.2.3.1 Companion Diagnostics

6 Immuno-Oncology Assays Market, By Product
6.1 Introduction
6.2 Consumables
6.2.1 Consumables Segment Will Continue to Dominate the Immuno-Oncology Assays Market During the Forecast Period
6.3 Software
6.3.1 The Need to Deliver Accurate and Timely Analysis of Diagnostic Tests has Resulted in the Increased Adoption of Software

7 Immuno-Oncology Assays Market, By Technology
7.1 Introduction
7.2 PCR
7.2.1 Emergence of Advanced PCR Technologies to Support Market Growth
7.3 Immunoassay
7.3.1 Immunoassays Have the Potential to Reduce Cancer Mortality Rate By Facilitating the Diagnosis of Cancer in the Early Stage
7.4 Ngs
7.4.1 Ngs Segment to Register the Highest Growth Rate During the Forecast Period
7.5 Flow Cytometry
7.5.1 Flow Cytometry Plays A Critical Role in Clinical Research Studies
7.6 Other Technologies

8 Immuno-Oncology Assays Market, By Indication
8.1 Introduction
8.2 Lung Cancer
8.2.1 Increasing R&D Activities on Lung Immuno-Oncology Assays is A Key Market Driver
8.3 Colorectal Cancer
8.3.1 High Success Rate of Immuno-Oncology Assays in Crc Treatment Decisions to Drive Market Growth
8.4 Melanoma
8.4.1 Growing Cases of Melanoma to Drive Market Growth
8.5 Bladder Cancer
8.5.1 Bladder Cancer Segment to Witness Slower Growth Owing to the Limited Adoption of Immuno-Oncology Assays
8.6 Other Cancers

9 Immuno-Oncology Assays Market, By Application
9.1 Introduction
9.2 Research Applications
9.2.1 Rising Prominence of Biomarker-Based Drug Development and Clinical Trials to Drive the Research Applications Market
9.3 Clinical Diagnostics
9.3.1 Benefits of Immuno-Oncology Assays are Driving Its Adoption in Clinical Diagnostics

10 Immuno-Oncology Assays Market, By Region
10.1 Introduction
10.2 North America
10.2.1 US
10.2.1.1 Increasing Demand for Immunotherapy Medicine Forms A Key Driver of Market Growth in the US
10.2.2 Canada
10.2.2.1 High Burden of Cancer to Drive the Demand for Immuno-Oncology Assays
10.3 Europe
10.3.1 Rising Focus on Biomarker Development in Several Eu Countries to Support Market Growth
10.4 Asia Pacific
10.4.1 Increasing Demand for Better Healthcare Services in Developing Economies Will Contribute to Market Growth
10.5 Rest of the World

11 Competitive Landscape
11.1 Overview
11.2 Vendor Benchmarking
11.3 Competitive Leadership Mapping
11.3.1 Visionary Leaders
11.3.2 Innovators
11.3.3 Dynamic Differentiators
11.3.4 Emerging Companies
11.4 Market Ranking Analysis, 2017
11.5 Competitive Situation and Trends
11.5.1 Collaborations
11.5.2 Product Launches
11.5.3 Acquisitions
11.5.4 Expansions

12 Company Profiles
12.1 Thermo Fisher Scientific, Inc.
12.2 Roche Diagnostics
12.3 Agilent Technologies, Inc.
12.4 Illumina, Inc.
12.5 Nanostring Technologies, Inc.
12.6 Sartorius AG
12.7 Foundation Medicine
12.8 HTG Molecular Diagnostics, Inc.
12.9 Qiagen
12.10 Merck
12.11 Perkinelmer

13 Appendix
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Subscription Portal
13.4 Available Customizations
13.5 Related Reports
13.6 Author Details

List of Tables
Table 1 Market, By Product, 2016–2024 (USD Million)
Table 2 Market for Consumables, By Region, 2016–2024 (USD Million)
Table 3 North America: Market for Consumables, By Country, 2016–2024 (USD Million)
Table 4 Market for Software, By Region, 2016–2024 (USD Million)
Table 5 North America: Market for Software, By Country, 2016–2024 (USD Million)
Table 6 Market, By Technology, 2016–2024 (USD Million)
Table 7 Market for PCR, By Region, 2016–2024 (USD Million)
Table 8 North America: Market for PCR, By Country, 2016–2024 (USD Million)
Table 9 Market for Immunoassay, By Region, 2016–2024 (USD Million)
Table 10 North America: Market for Immunoassay, By Country, 2016–2024 (USD Million)
Table 11 Market for Ngs, By Region, 2016–2024 (USD Million)
Table 12 North America: Market for Ngs, By Country, 2016–2024 (USD Million)
Table 13 Market for Flow Cytometry, By Region, 2016–2024 (USD Million)
Table 14 North America: Market for Flow Cytometry, By Country, 2016–2024 (USD Million)
Table 15 Market for Other Technologies, By Region, 2016–2024 (USD Million)
Table 16 North America: Market for Other Technologies, By Country, 2016–2024 (USD Million)
Table 17 Market, By Indication, 2016–2024 (USD Million)
Table 18 Market for Lung Cancer, By Region, 2016–2024 (USD Million)
Table 19 North America: Market for Lung Cancer, By Country, 2016–2024 (USD Million)
Table 20 Immun0-Oncology Assays Market for Colorectal Cancer, By Region, 2016–2024 (USD Million)
Table 21 North America: Immun0-Oncology Assays Market for Colorectal Cancer, By Country, 2016–2024 (USD Million)
Table 22 Immun0-Oncology Assays Market for Melanoma, By Region, 2016–2024 (USD Million)
Table 23 North America: Immun0-Oncology Assays Market for Melanoma, By Country, 2016–2024 (USD Million)
Table 24 Immun0-Oncology Assays Market for Bladder Cancer, By Region, 2016–2024 (USD Million)
Table 25 North America: Immun0-Oncology Assays Market for Bladder Cancer, By Country, 2016–2024 (USD Million)
Table 26 Market for Other Cancers, By Region, 2016–2024 (USD Million)
Table 27 North America: Market for Other Cancers, By Country, 2016–2024 (USD Million)
Table 28 Market, By Application, 2016–2024 (USD Million)
Table 29 Market for Research Applications, By Region, 2016–2024 (USD Million)
Table 30 North America: Market for Research Applications, By Country, 2016–2024 (USD Million)
Table 31 Market for Applications, By Clinical Diagnostics, 2016–2024 (USD Million)
Table 32 North America: Market for Clinical Diagnostics, By Country, 2016–2024 (USD Million)
Table 33 Market, By Region, 2016–2024 (USD Million)
Table 34 North America: Market, By Country, 2016–2024 (USD Million)
Table 35 North America: Market, By Product, 2016–2024 (USD Million)
Table 36 North America: Market, By Technology, 2016–2024 (USD Million)
Table 37 North America: Market, By Indication, 2016–2024 (USD Million)
Table 38 North America: Market, By Application, 2016–2024 (USD Million)
Table 39 US: Market, By Product, 2016–2024 (USD Million)
Table 40 US: Market, By Technology, 2016–2024 (USD Million)
Table 41 US: Market, By Indication, 2016–2024 (USD Million)
Table 42 US: Market, By Application, 2016–2024 (USD Million)
Table 43 Canada: Immuno-Oncology Assays Market, By Product, 2016–2024 (USD Million)
Table 44 Canada: Market, By Technology, 2016–2024 (USD Million)
Table 45 Canada: Market, By Indication, 2016–2024 (USD Million)
Table 46 Canada: Market, By Application, 2016–2024 (USD Million)
Table 47 Europe: Market, By Product, 2016–2024 (USD Million)
Table 48 Europe: Market, By Technology, 2016–2024 (USD Million)
Table 49 Europe: Market, By Indication, 2016–2024 (USD Million)
Table 50 Europe: Market, By Application, 2016–2024 (USD Million)
Table 51 APAC: Market, By Product, 2016–2024 (USD Million)
Table 52 APAC: Market, By Technology, 2016–2024 (USD Million)
Table 53 APAC: Immuno-Oncology Assays Market, By Indication, 2016–2024 (USD Million)
Table 54 APAC: Market, By Application, 2016–2024 (USD Million)
Table 55 RoW: Market, By Product, 2016–2024 (USD Million)
Table 56 RoW: Assays Market, By Technology, 2016–2024 (USD Million)
Table 57 RoW: Market, By Indication, 2016–2024 (USD Million)
Table 58 RoW: Market, By Application, 2016–2024 (USD Million)
Table 59 Vendor Benchmarking By Growth Strategy
Table 60 Collaborations, 2016–2018
Table 61 Product Launches, 2016–2018
Table 62 Acquisitions, 2016-2018
Table 63 Expansions, 2015 to 2018

List of Figures
Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Data Triangulation
Figure 6 Market, By Application, 2018 vs 2024 (USD Million)
Figure 7 Market, By Product, 2018 vs 2024 (USD Million)
Figure 8 Market, By Indication, 2018 vs 2024 (USD Million)
Figure 9 Market, By Technology, 2018 vs 2024 (USD Million)
Figure 10 Geographical Snapshot of the Immuno-Oncology Assays Market
Figure 11 Increasing Adoption of Targeted Therapy Over Traditional Therapy is A Key Driver for the Immuno-Oncology Assays Market
Figure 12 Consumables Segment to Account for Largest Share in North American Immuno-Oncology Assays Market
Figure 13 Research Applications to Continue to Dominate the Immuno-Oncology Assays Market in 2024
Figure 14 PCR Segment Will Continue to Dominate the Immuno-Oncology Assays Market in 2024
Figure 15 APAC Will Be the Fastest-Growing Market From 2018 to 2024
Figure 16 Immuno-Oncology Assays Market: Drivers, Restraints, and Opportunities
Figure 17 North America: Immuno-Oncology Assays Market Snapshot
Figure 18 Asia Pacific: Immuno-Oncology Assays Market Snapshot
Figure 19 Immuno-Oncology Assays Market (Global), Competitive Leadership Mapping, 2017
Figure 20 Rank of Companies in the Global Immuno-Oncology Assays Market, 2017
Figure 21 Thermo Fisher Scientific: Company Snapshot (2017)
Figure 22 Roche Diagnostics: Company Snapshot (2017)
Figure 23 Agilent Technologies: Company Snapshot (2017)
Figure 24 Illumina: Company Snapshot (2017)
Figure 25 Nanostring Technologies: Company Snapshot (2017)
Figure 26 Sartorius AG: Company Snapshot (2017)
Figure 27 HTG Molecular Diagnostics: Company Snapshot (2017)
Figure 28 Qiagen: Company Snapshot (2017)
Figure 29 Merck: Company Snapshot (2017)
Figure 30 Perkinelmer: Company Snapshot (2017)

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
5 of 6
  • Agilent Technologies, Inc.
  • Foundation Medicine
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Merck
  • Nanostring Technologies, Inc.
  • Perkinelmer
  • Qiagen
  • Roche Diagnostics
  • Sartorius AG
  • Thermo Fisher Scientific, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4752892
Adroll
adroll